Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. In addition, the company is developing BAN2401, which has completed Phase II clinical trial for the treatment of Alzheimer's disease, as well as Elenbecestat that is in Phase III clinical trial for treatment of early Alzheimer's disease. The company's Phase II clinical trial products comprise Opicinumab for MS; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild Alzheimer's disease. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases; and C4 Therapeutics to develop therapies for treating Alzheimer's disease. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone617-679-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.45 billion
Profitability
Miscellaneous
Employees7,800
OptionableOptionable
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen Inc (NASDAQ:BIIB) posted its quarterly earnings data on Tuesday, January, 29th. The biotechnology company reported $6.99 earnings per share for the quarter, topping the Zacks' consensus estimate of $6.72 by $0.27. The biotechnology company earned $3.53 billion during the quarter, compared to analysts' expectations of $3.39 billion. Biogen had a return on equity of 40.53% and a net margin of 32.94%. The business's quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm earned $5.26 EPS. View Biogen's Earnings History.
When is Biogen's next earnings date?
What guidance has Biogen issued on next quarter's earnings?
Biogen updated its FY19 earnings guidance on Tuesday, January, 29th. The company provided earnings per share guidance of $28-29 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $27.98. The company issued revenue guidance of $13.6-13.8 billion, compared to the consensus revenue estimate of $13.63 billion.Biogen also updated its FY 2019 guidance to $28.00-29.00 EPS.
What price target have analysts set for BIIB?
26 brokerages have issued 1-year target prices for Biogen's stock. Their predictions range from $262.15 to $436.00. On average, they anticipate Biogen's stock price to reach $378.2365 in the next twelve months. This suggests a possible upside of 12.9% from the stock's current price. View Analyst Price Targets for Biogen.
What is the consensus analysts' recommendation for Biogen?
26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 7 hold ratings and 19 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biogen.
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. HC Wainwright analysts commented, "Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (2/19/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $400 12-month price target. Biogen hosted a webcast this morning to outline its strategy in multiple sclerosis (MS), focusing on the pipeline as well as lifecycle management for the $9B base business. We saw detailed commentary about specific lifecycle management plans as most important. We think BIIB098 could be another option for new patients or Tecfidera switches. Although investors remain focused on aducanumab, we think understanding long-term MS growth is of similar importance." (12/12/2018)
- 3. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call and BAN2401 data last week." (7/31/2018)
Has Biogen been receiving favorable news coverage?
Media coverage about BIIB stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biogen earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), argenx (ARGX), Allogene Therapeutics (ALLO), Ablynx (ABLYF), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO) and Denali Therapeutics (DNLI).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Mr. Michel Vounatsos, CEO & Director (Age 57)
- Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
- Ms. Susan H. Alexander, Exec. VP, Chief of Legal & Corp. Services and Corp. Sec. (Age 62)
- Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
- Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)
Who are Biogen's major shareholders?
Biogen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.22%), Oregon Public Employees Retirement Fund (7.10%), Northern Trust Corp (1.48%), Geode Capital Management LLC (1.38%), Bank of New York Mellon Corp (1.14%) and Massachusetts Financial Services Co. MA (0.95%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
Which institutional investors are selling Biogen stock?
BIIB stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Canada Pension Plan Investment Board, Macquarie Group Ltd., Acadian Asset Management LLC, Nomura Asset Management Co. Ltd., Eaton Vance Management, First Quadrant L P CA and Orbimed Advisors LLC. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock and Michael D Ehlers. View Insider Buying and Selling for Biogen.
Which institutional investors are buying Biogen stock?
BIIB stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Prudential Financial Inc., Parnassus Investments CA, Amundi Pioneer Asset Management Inc., Kiltearn Partners LLP, Geode Capital Management LLC, Northern Trust Corp and Two Sigma Advisers LP. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $335.16.
How big of a company is Biogen?
Biogen has a market capitalization of $65.93 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.
What is Biogen's official website?
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.
MarketBeat Community Rating for Biogen (NASDAQ BIIB)
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
